ROMANA 3: a phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia

BACKGROUND: Cancer anorexia–cachexia is a debilitating condition frequently observed in NSCLC patients, characterized by decreased body weight, reduced food intake, and impaired quality of life. Anamorelin, a novel selective ghrelin receptor agonist, has anabolic and appetite-enhancing activities. P...

Descripción completa

Detalles Bibliográficos
Autores principales: Currow, D., Temel, J. S., Abernethy, A., Milanowski, J., Friend, J., Fearon, K. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834076/
https://www.ncbi.nlm.nih.gov/pubmed/28472437
http://dx.doi.org/10.1093/annonc/mdx192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5834076/
https://www.ncbi.nlm.nih.gov/pubmed/28472437
http://dx.doi.org/10.1093/annonc/mdx192

Ejemplares similares